Back to CVE records
Medium 4.7Published Sep 30, 2026

CVE-2026-102843gedelumbung HospitalManagement Endpoint data_galeri.php hapus path traversal

Updated under an hour ago ()

Does this affect you?

It affects gedelumbung HospitalManagement. Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

A security flaw has been discovered in gedelumbung HospitalManagement up to c2d45543789a3887067d3915f69d44cfc2cf76a8. This affects the function hapus of the file application/modules/admin/controllers/data_galeri.php of the component Endpoint. Performing a manipulation of the argument gbr results in path traversal. The attack can be initiated remotely. The exploit has been released to the public and may be used for attacks. Continious delivery with rolling releases is used by this product. Therefore, no version details of affected nor updated releases are available. The project was informed of the problem early through an issue report but has not responded yet.

CVSS
4.7 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:L/A:L/E:P/RL:X/RC:C
Weakness (CWE)
CWE-22
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
VulDB
NVD analysis
Deferred
Record last updated
Oct 2, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

Affected products
gedelumbung HospitalManagement
gedelumbung:hospitalmanagement
c2d45543789a3887067d3915f69d44cfc2cf76a8
CNA record

References

  • vdb-entry, technical-description
  • signature, permissions-required
  • third-party-advisory
  • third-party-advisory
  • exploit, issue-tracking
  • product

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.